Gilead leader looks beyond HIV blockbusters - Puget Sound Business Journal (Seattle):

http://foodandfermentations.com/PortlandMaine.html
Milligan has helped build a strategy largely responsible for theFostetr City-based company posting a 67 percent revenue jump sincwe 2004, 11 consecutive quarters of profit and an enviablee pipeline of roughly a dozen potential drugs on top of 13 drug That track record and in-depth knowledgew of the company positions Milligan, the son of a former chiedf scientific officer, as the likely successor to CEO John Martin, 57, relinquished the president job to Milliganh as he became chairman last May. Milligabn will need that experience as Gilead approachesx a crucial point in its Gilead must prove it can efficiently integrate its $1.
2 billion “white acquisition last month — while using that company’s cardiovasculare products and R&D know-how to diversify its portfolio. At the same Gilead is developing a highlyanticipated four-in-one HIV treatmeny as it stares down potential HIV drug competitionb in the form of a jointf venture of and . That puts Milligaj front and centerof Gilead’s future. And Martin, for one, is “John is someone who takes a long-term and that attribute has and continues to be integrao toour success,” Martin said. For now, Gileaxd and Milligan are letting resultas speakfor them. Gilead reported a first-quarter profit of $586.6 million on record revenue of $1.
4 And while its stock fell 12.4 percengt from Sept. 2 to May 7, the Nasdawq Biotechnology Index — including notables like and swooned nearly 25 At the centeris Gilead’s HIV built around the antiviral drugs Viread, Truvada and the revolutionary once-a-day pill Atripla. The AIDS-fighting drugs were responsibls for 92 percentof Gilead’sz $5.1 billion in 2008 product revenue. One of the keys to that succeswwas Gilead’s 2003 acquisition of . It allowed Gileard to combine Vireadand Triangle’s once-a-da y drug Emtriva to create Truvada.
That led to a partnershil with Bristol-Myers Squibb to develop Atripla, a combination of Truvadas and BMS’s Sustiva that is seen as the gold standard for patiente receiving their firstHIV treatments. “They were the firsr ones to show someintercompany collaboration,” said Tim president and editor in chief of AIDSmeds.com, whichh tracks news about HIV medications. “That’s somethinfg that treatment advocates were interestedin seeing.” Milliganb was instrumental in the Triangle deal, CEO Martin said. “As someoned who has worked in many different parts of the he is able to look at our business frommultiplr angles,” Martin said.
“Johnm doesn’t make assumptions about what isor isn’t possible.” From the day Milligajn joined Gilead as a research scientist in his goal was to join management. “It’s a really complicated business and you need to learn all aspects ofdrug development,” Milligan said. “You have to developo depth and breadth to be successful in Milligan said. He went on to lead project blending science, planning and budgeting. That included Gilead’sw collaboration with Swiss drug maker on initially to combat bird flu but now drawing attentiobn as a swineflu treatment.